rabeprazole + esomeprazole

The entry **rabeprazole vs. esomeprazole-National Taiwan University Hospital-Helicobacter pylori infection** refers to a clinical research context evaluating the comparative efficacy of two proton pump inhibitors (PPIs), rabeprazole and esomeprazole, in the treatment of *Helicobacter pylori* infection. Conducted by National Taiwan University Hospital, the study (NCT00161200) focuses on how CYP2C19 genetic polymorphisms—which categorize patients as poor or extensive metabolizers—influence the pharmacokinetic and pharmacodynamic profiles of these drugs during short-term triple therapy. Both agents function by irreversibly inhibiting the gastric H+/K+-ATPase pump in parietal cells, thereby suppressing acid secretion and creating an environment conducive to antibiotic activity for bacterial eradication. Rabeprazole is notable for its significant non-enzymatic metabolic pathway, potentially making it less dependent on CYP2C19 status compared to esomeprazole.

Brand names

ParietAciphexNexium

Other names

rabeprazoleesomeprazole